References
- Zheng ZL, Liu J, Cheng XM. Cause analysis and solution of ABO positive and negative stereotypes inconsistency in 51 cases. Chin Mod Med. 2021;28(29):170–173. doi:10.3969/j.issn.1674-4721.2021.29.049.
- Shang H, Wang YS, Shen ZY. National operating procedures for clinical examination. 4th ed. Beijing: People's Medical Publishing House. 2015; p. 118–143.
- Yudin J, Heddle NM. A 13-question approach to resolving serological discrepancies in the transfusion medicine laboratory. Lab Med. 2014 Summer;45(3):193–206. doi:10.1309/LMEWVSNT2F3O5JDN
- Sun Y, Wang XN, Liu B. Clinical analysis of positive and negative typification of blood group in 152 cases. Chinese J Labor Diag. 2020;24(7):1218.
- Ma HL, Yun ZQ, Yang B, et al. Application of"three step analysis"of complicated ABO blood group. J Clin Hemat. 2011;24(2):75–77. doi:10.3969/j.issn.1004-2806-B.2011.01.005.
- Liu ZY, Zhang GQ, Yu WZ, et al. Experimental study of hypercoagulability in patients with multiple myeloma. J Exp Hemat. 2015;23(1):142–145. doi:10.7534/j.issn.1009-2137.2015.01.027.
- Park J, Jekarl DW, Park SY, et al. Combined group I and III ABO discrepancies in multiple myeloma with IgG-lambda type: A case report. Med Princ Pract. 2017;26(1):90–92. doi:10.1159/000450579
- Cui Y, Du J, Yang SM, et al. The influencing factors and treatment of blood grouping and cross matching in patients with multiple myeloma. Chin J Cell Mol Immunol. 2017;33(10):1419–1421. doi:10.13423/j.cnki.cjcmi.008465.
- Cheng J, Jiang M, Lin CY, et al. Cause analysis and treatment of ABO blood type abnormality in patients with multiple myeloma. Chin J Clin Lab Sci. 2020;38(6):440–442. doi:10.13602/j.cnki.jcls.2020.06.13.
- Cao HR, Meng XJ, Wang ZJ, et al. Analysis and report of ABO subtype identification results: one case report of B(A)04 subtype. Journal of Clinical Hematology. 2017;30(2):152–154. doi:10.13201/j.issn.1004-2806-b.2017.02.024.
- Meny GM. Recognizing and resolving ABO discrepancies. Immunohematol. 2017;33(2):76–81. doi:10.21307/immunohematology-2019-012
- Xie HY, Zhou ZX, Gu HH, et al. Blood type incompatibility caused by cold agglutination: a study of 16 cases. Chinese J Blood Trans. 2021;34(1):40–43. doi:10.13303/j.cjbt.issn.1004-549x.2021.01.013.
- Yang R, Luo YP, Xin H. Autoantibody combined with anti-Wra in a patient with autoimmune hemolytic anemia. Chinese J Blood Trans. 2019;32(07):718–720. doi:10.13303/j.cjbt.issn.1004-549x.2019.07.031.
- Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766. doi:10.1056/NEJMoa1606038
- Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–981. doi:10.1182/blood-2017-05-785246
- Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood comp atibility testing. Transfusion. 2015;55(6pt2):1545–1554. doi:10.1111/trf.13069
- Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555–1562. doi:10.1111/trf.13150
- Liu F, Liu J. Possible insensitivity of the polybrene antibody screen to detect anti-Jka. Ann Clin Lab Sci. 2006;36(1):101–102.
- Song J, Kong YK, Wang SY, et al. To remove monoclonal anti-CD38 interference from compatibility testing:A simple method. Chinese J Blood Trans. 2021;34(9):974–977. doi:10.13303/j.cjbt.issn.1004-549x.2021.09.010.
- Noiret L, Slater A, Higgins JM. Determinants of red blood cell alloantibody detection duration: analysis of multiply alloimmunized patients supports peritransfusion factors. Transfusion. 2017;57(8):1930–1937. doi:10.1111/trf.14157
- Hou RQ, Yang HY, Cui YP, et al. Analysis of the results of irregular antibody identification in patients and its clinical significance. J Exp Hemat. 2020;28(3):961–966. doi:10.19746/j.cnki.issn1009-2137.2020.03.040.